News & media

Back to all news

Cellanyx Diagnostics Joins TreeHouse Health as New Portfolio Company

MINNEAPOLIS (June 26, 2015) – TreeHouse Health introduces Cellanyx Diagnostics as a new portfolio company.

TreeHouse Health (http://www.TreeHouse-Health.com), an innovation center for emerging and established companies in healthcare, today announced an investment in Cellanyx Diagnostics, a Boston, Massachusetts-based company. Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision-making, initially in stratifying risk in men with prostate cancer.

“The technology Cellanyx is developing could be game-changing for the healthcare industry. We are very excited to support the company. Cellanyx is an excellent addition to TreeHouse Health,” says John Blank, M.D., Chairman of TreeHouse Health.

The Cellanyx platform employs biopsy-on-a-chip technology to analyze multiple phenotypic, biochemical and physical markers of individual living cells cultured from fresh biopsy samples. The company’s suite of biomarkers represents multiple biological pathways and morphological, metabolic and biophysical cellular characteristics such as cell motility and adhesion that are inaccessible with other methods.

Cellanyx has demonstrated clinical proof-of concept with its lead product in development, a diagnostic to improve risk stratification in men with low and intermediate Gleason grade prostate cancer and thereby reduce over diagnosis and overtreatment. The company’s initial clinical data have been presented at several major meetings, most recently the American Urological Association annual meeting. The ability to distinguish indolent from aggressive cancer is one of the key challenges managing prostate cancer patients. The lack of more precise risk stratification tools is a major reason why 144,000 patients in the U.S. annually are over-treated with surgery or radiation.

“Cellanyx has made significant progress in demonstrating the potential of our novel live cell diagnostic platform,” said Ashok Chander, PhD, CEO of Cellanyx. “We appreciate the support from TreeHouse Health in advancing our prostate test and other applications of our platform such as breast, bladder and kidney cancers.”

The Cellanyx team will have a presence at the TreeHouse Health space to complement their operations in Boston. The Minneapolis location boasts 13,000 sq. ft. of shared workspace, at the TreeHouse Health facility in the Loring Park neighborhood. TreeHouse Health portfolio companies also have access to local and national resources connected with TreeHouse Health.

About Cellanyx Diagnostics

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with low and intermediate grade prostate cancer and thereby reduce overtreatment. Learn more at www.cellanyx.com.

About TreeHouse Health LLC

Launched in October 2013, TreeHouse Health is a Minneapolis-based innovation center investing in and supporting entrepreneurial growth for both large and emerging companies in healthcare. To date, TreeHouse Health has invested in eight early-stage companies in healthcare and is partnered with Blue Cross and Blue Shield of Minnesota (BCBS) and Hennepin County Medical Center (HCMC). Learn more at TreeHouse-Health.com. Interested in joining TreeHouse Health? Visit http://treehouse-health.com/join-us or email a business plan to info@treehouse-health.com.